Praxis Precision Medicines (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.
The company’s pipeline includes several lead candidates at various stages of development. PRAX-562 is a selective persistent sodium current inhibitor being evaluated for severe epilepsies and other hyperexcitability disorders. PRAX-944, a T-type calcium channel blocker, is under investigation for essential tremor. PRAX-114, a neuroactive steroid that modulates GABAA receptors, is in development for major depressive disorder and postpartum depression. Additional programs, such as PRAX-330 and early research efforts targeting novel ion channel subtypes, further expand the company’s therapeutic reach.
Founded in 2015 and headquartered in Boston, Massachusetts, Praxis Precision Medicines conducts preclinical and clinical research primarily in the United States, with clinical trial sites across North America and Europe. The company has built a platform that integrates genetic discovery, patient stratification and biomarker development to accelerate the translation of scientific findings into targeted treatments. By collaborating with academic institutions and leveraging external partnerships, Praxis aims to optimize its clinical strategy and deliver data-driven insights for regulatory interactions.
Leadership at Praxis includes Winston W. Yen, M.D., co-founder and Chief Executive Officer, who brings experience in neuroscience drug development, and a management team with expertise spanning medicinal chemistry, clinical development and regulatory affairs. The company’s governance and scientific advisory board feature experts in neurology, genetics and drug discovery, supporting a strategy focused on precision medicine for CNS diseases.
